Purpose: To assess the safety and efficacy of canaloplasty (360-degree viscodilation and tensioning of the Schlemm canal) in Whites with open-angle glaucoma (OAG).
Methods: In a prospective study, 32 consecutive patients with medically uncontrolled OAG underwent primary canaloplasty with a follow-up time of more than 1 year. Laser goniopuncture was performed if postoperative intraocular pressure (IOP) was above 16 mmHg. IOP, number of antiglaucomatous medications, best-corrected visual acuity, and intraoperative and postoperative complications were recorded. Complete success was defined as an IOP ≤21, 18, and 16 mm Hg without medications, and qualified success with or without medications, respectively.
Results: The mean IOP dropped from 27.3±5.6 mm Hg preoperatively to 12.8±1.5 mm Hg at 12 months and 13.1±1.2 mm Hg at 18 months (P<0.001). The complete success rate of an IOP ≤21, 18, and 16 mm Hg was 93.8% [95% confidence interval (CI) 0.86-1.0], 84.4% (95% CI 0.73-0.98), and 74.9% (95% CI 0.61-0.92), respectively, at 12 months. Laser goniopuncture was performed on 6 eyes (18.1%) 3.3±2.1 months postoperatively. The mean IOP was 20.6±4.2 mm Hg before and 14.2±2.2 mm Hg after goniopuncture. The number of medications dropped from 2.7±0.5 before surgery to 0.1±0.3 after surgery (P<0.001). The postoperative best-corrected visual acuity at last visit (0.38±0.45; range: 0 to 1.8) was comparable with that of preoperative values (0.36±SD 0.37; range: 0 to 1.6) (P=0.42). In all but 1 eye, canaloplasty was completed. Minor intraoperative or postoperative complications like Descemet membrane detachment in 2 eyes, elevated IOP in 1 eye, and suprachoroidal passage of the catheter in 4 eyes were encountered. In 1 eye, circumferential cannulation of the Schlemm canal was impossible.
Conclusions: Canaloplasty seems to be a promising and effective surgical procedure in Whites with OAG. Postoperative IOP levels are in the low-to-mid-teens. The procedure can be regarded as safe, but has its own profile of complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/IJG.0b013e3181e3d46e | DOI Listing |
J Glaucoma
February 2025
Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Research Center and Division of Ophthalmology Informatics and Data Science, University of California San Diego.
Prcis: In a diverse database ( All of Us ), we report significant dose-response associations between alcohol use frequency and glaucoma, with alcohol use of 4 or more drinks per week associated with significantly increased odds of glaucoma.
Purpose: Current evidence on the association between alcohol use and primary open angle glaucoma (POAG) is mixed. We utilize the diverse All of Us Research Program to further examine this relationship.
Am J Ophthalmol
December 2024
From the Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St Louis (M.O.G., M.A.K.), St Louis, Missouri, USA.
Purpose: To determine the rate of visual field (VF) loss before and after the diagnosis of primary open angle glaucoma (POAG) in the Ocular Hypertension Treatment Study (OHTS).
Design: Prespecified analyses of data collected prospectively in a clinical trial with extended follow-up.
Setting And Participants: Participants who developed POAG during OHTS 1 and 2 (February 1994 to December 2008) constitute an inception cohort.
JAMA Ophthalmol
January 2025
Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Importance: Primary open-angle glaucoma (POAG) polygenic risk scores (PRSs) continue to be evaluated in primarily European-ancestry populations despite higher prevalence and worse outcomes in African-ancestry populations.
Objective: To evaluate how established POAG PRSs perform in African-ancestry samples from the Genetics in Glaucoma Patients of African Descent (GIGA), Genetics of Glaucoma in Individuals of African Descent (GGLAD), and Million Veteran Program (MVP) datasets and compare these with European-ancestry samples.
Design, Setting, And Participants: This was a multicenter, cross-sectional study of POAG cases and controls from Tanzania, South Africa, Nigeria, Ghana, and the US.
PLoS One
October 2024
Department of Ophthalmology, Medical University of Białystok, Białystok, Poland.
J Glaucoma
February 2025
Department of Ophthalmology, Medical Faculty Carl Gustav Carus, Technische Universität, Fetscherstrasse, Dresden, Germany.
Prcis: The Preserflo MicroShunt effectively lowered intraocular pressure in primary high and normal pressure open angle glaucoma.
Purpose: To evaluate the efficacy and safety of the Preserflo MicroShunt in patients with primary open angle glaucoma (POAG) and the 2 variants high (HPG) and normal pressure glaucoma (NPG) after 1 year.
Methods: Single-center prospective interventional case series consecutively including eyes of White/European patients with POAG, who received the Preserflo MicroShunt as a primary and standalone glaucoma intervention.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!